William Chou
Chief Executive Officer bij PASSAGE BIO, INC.
Vermogen: - $ op 31-03-2024
Profiel
William Chou is currently the President, Chief Executive Officer & Director at Passage Bio, Inc. Prior to his current position, he served as the Chief Executive Officer at Aruvant Sciences, Inc. Dr. Chou completed his undergraduate degree at Princeton University, followed by an MBA from Yale School of Management.
He also holds a doctorate degree from the University of Pittsburgh School of Medicine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
PASSAGE BIO, INC.
-.--% | 18-03-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van William Chou
| Bedrijven | Functie | Begin |
|---|---|---|
| PASSAGE BIO, INC. | Chief Executive Officer | 10-10-2022 |
Eerdere bekende functies van William Chou
| Bedrijven | Functie | Einde |
|---|---|---|
Aruvant Sciences, Inc.
 Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Chief Executive Officer | - |
Opleiding van William Chou
| Princeton University | Undergraduate Degree |
| Yale School of Management | Masters Business Admin |
| University of Pittsburgh School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PASSAGE BIO, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
